Sunpill maker rejects NAD’s finding
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Division May 10 says it will refer Pure Pharmaceuticals to the Federal Trade Commission for possible enforcement action after the Miami-based firm declined to fully comply with NAD's recommendations for changes in claims for its Sunpillproduct. NAD contacted Pure in March to question why claims it challenged in a compliance review remained on the firm's Web site. Pure provided a list of changes it made, but NAD said it "remained concerned that the advertising continues to convey the message that sunscreen is unnecessary, does not provide adequate protection against the sun or that Sunpill is the first line of defense in sun protection." Disclosures the firm added "contradict the claims they are intended to qualify" or "are not in close proximity to the underlying claims," NAD said, adding its procedures require it to refer firms to FTC if they fail to comply with its recommendations...